Indrayani Biotech Limited (BOM:526445)

Indrayani Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	42.56	2.88	5.82	30.37	15.03
Short-Term Investments	-	262.11	296.7	96.58	6.77
Cash & Short-Term Investments	42.56	265	302.52	126.94	21.8
Cash Growth	-83.94%	-12.40%	138.31%	482.33%	221.19%
Accounts Receivable	585.8	586.9	395.29	299.72	140.99
Other Receivables	23.67	405.58	245.41	177.15	12.83
Receivables	631.36	1,078	709.17	500.53	153.82
Inventory	377.84	413.42	423.51	122.14	15.32
Other Current Assets	535.45	22.84	14.56	25.62	4.97
Total Current Assets	1,587	1,779	1,450	775.23	195.91
Property, Plant & Equipment	636.08	600.04	593.77	478.56	259.38
Long-Term Investments	2.79	2.48	2.23	2.23	0.01
Goodwill	233.47	233.47	233.47	233.47	38.41
Other Intangible Assets	-	0.01	-	0.15	-
Long-Term Deferred Tax Assets	24.4	-0.49	3.32	0.38	-
Other Long-Term Assets	50.32	64.04	57.46	69.6	20.3
Total Assets	2,534	2,679	2,340	1,560	514.01

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	140.58	235.83	373.9	227.38	58.2
Accrued Expenses	-	61.43	55.3	54.82	22.03
Short-Term Debt	704.18	704.36	398.51	314.31	111.03
Current Portion of Long-Term Debt	-	12.22	12.16	19.44	-
Current Portion of Leases	-	-	7.93	11.25	3.57
Current Income Taxes Payable	-	8.21	6.19	2.01	-
Current Unearned Revenue	-	0.35	0.33	0.12	-
Other Current Liabilities	85.05	2.44	16.4	89.77	-
Total Current Liabilities	929.82	1,025	870.72	719.1	194.82
Long-Term Debt	578.88	654.15	665.97	293.7	67.85
Long-Term Leases	-	-	40.67	63.16	5.5
Long-Term Deferred Tax Liabilities	4.74	-	-	0.14	0.14
Other Long-Term Liabilities	-	0.75	-	-	-
Total Liabilities	1,513	1,680	1,577	1,076	268.31

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	455.36	455.36	455.36	342.27	342.27
Additional Paid-In Capital	-	201.74	126.64	114.01	0.09
Retained Earnings	-	33.11	48.94	-13.36	-100.72
Comprehensive Income & Other	273.51	34.88	41.18	15.44	-
Total Common Equity	728.88	725.1	672.12	458.37	241.63
Minority Interest	291.97	274.07	90.54	-67.34	4.06
Shareholders' Equity	1,021	999.16	762.66	483.53	245.7
Total Liabilities & Equity	2,534	2,679	2,340	1,560	514.01

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	1,283	1,371	1,125	701.86	187.94
Net Cash (Debt)	-1,240	-1,106	-822.72	-574.92	-166.15
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-160.80	-24.28	-18.07	-13.22	-4.85
Filing Date Shares Outstanding	45.48	45.54	45.54	34.23	34.23
Total Common Shares Outstanding	45.48	45.54	45.54	34.23	34.23
Working Capital	657.39	754.51	579.04	56.13	1.08
Book Value Per Share	16.03	15.92	14.76	13.39	7.06
Tangible Book Value	495.4	491.61	438.65	224.75	203.22
Tangible Book Value Per Share	10.89	10.80	9.63	6.57	5.94

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error